Comparison of cefpodoxime proxetil with cefaclor in the treatment of sinusitis.

Abstract

The efficacy and tolerance of cefpodoxime proxetil were compared with those of cefaclor in a multicentre, international, prospective, double-blind, placebo-controlled study in adult outpatients suffering from acute sinusitis. At the end of treatment, cefpodoxime proxetil was more effective than cefaclor, producing complete clinical cure in 84% of cases (102/122) vs 68% of cases (77/114) in the cefaclor group (P = 0.01). The overall clinical efficacy (cure + improvement) was similar in the two groups with 95% (116/122) satisfactory responses in the cefpodoxime proxetil group and 93% (106/114) in the cefaclor group. Bacteriological response was similar with 95% eradication in the cefpodoxime proxetil group (55/58) vs 91% with cefaclor (63/69).

• Authors: P Gehanno, J Depondt, B Barry, M Simonet, H Dewever
• Journal: The Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 26 Suppl E Pg. 87-91 (Dec 1990) ISSN: 0305-7453 [Print] England
• PMID: 2127269 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Prodrugs
• cefpodoxime proxetil
• Cefaclor
• Ceftizoxime

Topics

• Acute Disease
• Adult
• Aged
• Aged, 80 and over
• Cefaclor (adverse effects, therapeutic use)
• Ceftizoxime (adverse effects, analogs & derivatives, therapeutic use)
• Female
• Humans
• Immunodiffusion
• Male
• Middle Aged
• Prodrugs (adverse effects, therapeutic use)
• Remission Induction
• Sinusitis (drug therapy, microbiology)